As the EU’s general pharmaceutical legislation enters a decisive phase, EHC have joined EURORDIS–Rare Diseases Europe, the European Patients’ Forum (EPF) and more than 70 additional patient organisations in calling on EU policymakers to safeguard strong and meaningful patient involvement at the European Medicines Agency (EMA) – including the retention of patient voting rights in the Committee for Medicinal Products for Human Use (CHMP).

In a joint statement first published on 10 March 2025, EURORDIS and EPF warned that Council negotiations risked removing patient representatives’ voting rights in the CHMP and reducing the number of voting patient members in the Pharmacovigilance and Risk Assessment Committee (PRAC) – the two EMA committees responsible for authorising and monitoring medicines in Europe.

The European Commission’s original proposal marked a milestone in formalising patient involvement in EU medicines regulation, introducing provisions for four patient representatives with voting rights on the CHMP and two on the PRAC. However, the Council agreement adopted on 4 June significantly weakens these provisions. It falls short of both the Commission’s ambition and the European Parliament’s position adopted in April 2024 in terms of patient involvement.

For over 25 years, patient representatives have contributed their lived experience to EU regulatory processes. Their insights strengthen trust, ensure that medicines respond to real-world needs, and complement clinical and scientific expertise.

Reducing patient involvement or removing voting rights would not only undo decades of progress – it would send a damaging signal that patient perspectives are no longer valued in decisions that directly affect their lives.

We are therefore proud to announce that EHC has endorsed this joint statement, which has now received widespread support from a growing number of patient organisations across the memberships of EPF and EURORDIS. This momentum reflects a shared concern across the community: the current direction of the pharmaceutical legislation risks undermining meaningful patient involvement. Together, we are raising our voices to ensure the final legislation can fully reflects patients’ lived experiences, expertise, and priorities, and does not diminish their role. This strong display of unity reinforces our collective commitment to ensuring that the future EU pharmaceutical framework truly serves the needs of patients by placing them at the heart of every decision.

Following the Coreper I agreement on 4 June, reached under the Polish Presidency of the Council of the EU, trilogue negotiations between the Council, the Parliament and the Commission are set to begin on 17 June. This final phase will shape the future of EU medicines regulation – and with it, the future of patient representation within the EMA.

The coming weeks are a crucial moment for EU institutions to enshrine meaningful patient involvement – not as a token gesture, but through full and equal voting rights.

That’s why patient organisations and advocates are also being urged to join EURORDIS and EPF’s #KeepPatientsVoting campaign and use its dedicated toolkit (find it HERE), which includes templates for social media and direct outreach to policymakers.